Addition of darbepoetin alfa to dose-dense chemotherapy: Results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide

Clinical Lung Cancer

Volumn 12, Issue 1, 2011, Pages 62-69

  Nagel, Sylke ^a   Kellner, Olaf ^b   Engel Riedel, Walburga ^c   Guetz, Sylvia ^d   Schumann, Christian ^e   Gieseler, Frank ^f   Schuette, Wolfgang ^a  

^a Krankenhaus Martha Maria   (Germany)

^b DESSAU MEDICAL CENTER   (Germany)

^c Hospital of Lung Diseases   (Germany)

^d Robert Koch Klinik   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Antineoplastic combined chemotherapy protocols; Erythropoietin; Lung neoplasms; Small cell lung carcinoma

Indexed keywords

CARBOPLATIN; ETOPOSIDE; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADD ON THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; EMBOLISM; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; PANCYTOPENIA; PATIENT ASSESSMENT; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 79551547839     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.3816/CLC.2011.n.009     Document Type: Article

References (55)

1. Stasi R, Amadori S, Littlewood TJ, et al. Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns. Oncologist 2005;10:539-54.
2. Waltzman RJ. Treatment of chemotherapy-related anemia with erythropoietic agents: current approaches and new paradigms. Semin Hematol 2004;41(suppl 7):9-16.
3. Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9.
4. Heatherington AC, Schuller J, Mercer AJ. Pharmacokinetics of novel erythropoi-esis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer 2001;84(suppl 1):11-6.
5. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-5.
6. Canon JL, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-84.
7. Glaspy J, Vadhan-Raj S, Patel R, et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 2006;24:2290-7.
8. Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004;9:696-707.
9. Senecal FM, Yee L, Gabrail N, et al. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40, 000 U weekly. Clin Breast Cancer 2005;6:446-54.
10. Birgegard G, Aapro MS, Bokemeyer C, et al. Cancer-related anemia: pathogen-esis, prevalence and treatment. Oncology 2005;68(suppl 1):3-11.
11. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689-92.
12. Dicato M. Anemia in cancer: some pathophysiological aspects. Oncologist 2003;8(1 suppl): 19-21.
13. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998;25(7 suppl): 43-6.
14. Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoi-etic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003;14:511-9.
15. Goodnough LT. Risks of blood transfusion. Anesthesiol Clin North America 2005;23:241-52 v.
16. Goodnough LT, Brecher ME, Kanter MH, et al. Transfusion medicine. First of two parts-blood transfusion. N Engl J Med 1999;340:438-47.
17. Vamvakas EC. Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials. Transfusion 1996;36:175-86.
18. Varlotto J, Stevenson MA. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 2005;63:25-36.
19. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24.
20. Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006;3: CD003407.
21. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403.
22. Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-34.
23. Pirker R, Ramlau RA, Schuette W, et al. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 2008;26:2342-9.
24. Taylor K, Ganly P, Charu V, et al. Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia. Blood 2005;106: (abstract 3556).
25. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20.
26. Charu V, Belani C P, Gill AN, et al. Efficacy and safety of every-2-week darbepo-etin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial. Oncologist 2007;12:727-37.
27. Gordon D, Nichols G, Ben-Jacob A, et al. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study. Oncologist 2008;13:715-24.
28. Smith RE, Jr, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040-50.
29. Smith RE, Jr, Tchekmedyian NS, Chan D, et al. A dose-and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 2003;88:1851-8.
30. Aapro MS, Birgegard G, Bokemeyer C, et al. Erythropoietins should be used according to guidelines. Lancet Oncol 2008;9:412-3.
31. Erythropoietin analogues: an unnecessary class of drugs. Lancet Oncol 2008;9:81.
32. Lappin TR, Maxwell A P, Johnston PG. Warning flags for erythropoiesis-stimulat-ing agents and cancer-associated anemia. Oncologist 2007;12:362-5.
33. Steinbrook R. Erythropoietin, the FDA, and oncology. N Engl J Med 2007;356:2448-51.
34. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
35. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-60.
36. Leyland-Jones B, Mahmud S. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:80, author reply 81-2.
37. Briefing Document FDA. Oncologic Drugs Advisory Committee (ODAC) meeting on 10 May 2007: Continuing reassessment of the risks of erythropoiesis-stim- ulating agents (ESAs) administered for the treatment of anemia associated with cancer chemotherapy. FDA-ODAC; 2007: http://www.fda.gov/ohrms/dockets/ac/07/ briefing/2007-4301b2-02-FDA.pdf.
38. Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with Erythropoiesis-stimulating agents. Oncologist 2008;13(3 suppl): 33-6.
39. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of eryth-ropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-70.
40. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132-49.
41. Briefing Document FDA. Oncologic Drugs Advisory Committee (ODAC) meeting on 13 March 2008: FDA Briefing material (including two appendices and errata). FDA-ODAC; 2008: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345b2-00- FDA-index.htm.
42. Grote T, Yeilding AL, Castillo R, et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2005;23:9377-86.
43. Manufacturers' Briefing Book. Background information for the Oncologic Drugs Advisory Committee (ODAC) meeting on 13 March 2008 (including one supplement). Amgen Inc. and Johnson & Johnson; 2008: http://www.fda.gov/ ohrms/dockets/ac/08/briefing/2008-4345b2-00-FDA-index.htm. Briefing Material page 2052 (Figure 2009) and Supplement page 2018 (Figure 2004).
44. Thatcher N, De Campos ES, Bell DR, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999;80:396-402.
45. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-32.
46. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-51.
47. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
48. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
49. Sprangers MA, Cull A, Groenvold M, et al. The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group. Qual Life Res 1998;7:291-300.
50. Thatcher N, Girling DJ, Hopwood P, et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 2000;18:395-404.
51. Tjan-Heijnen VC, Wagener DJ, Postmus PE. An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn. Ann Oncol 2002;13:1519-30.
52. Buyse M. Randomized designs in early trials of new cancer treatments: an overview. Drug Inf J 2000;34:387-96.
53. Barrett-Lee PJ, Bailey N P, O'Brien ME, et al. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000;82:93-7.
54. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102:301-15.
55. Ludwig H, Crawford J, Osterborg A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbe-poetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009;27:2838-47.